| abstract |
The present invention relates to compound of formula I and II, or its pharmaceutically acceptable salt; wherein R is selected from the group consisting of -H, -F, -Cl, -Br, -I, -NO 2 , -CH 3 , or -C 2 H 5 ; R 1 is selected from the group consisting of –H, or -CH 3 ; R 2 is selected from the group consisting of –H or a group of Formula III; wherein R 3 and R 4 are selected from the group consisting of –H, -CH 3 , -C 2 H 5 , -F, -Cl, -Br, -I, or -NO 2 ; the dotted line in compound of formula I and II indicates that the ring structure may contain a double bond. |